Amantadine in parkinson’s disease: modern possibilities of long-term therapy
The long-term therapy of Parkinson’s disease (PD) with dopaminergic drugs is naturally accompanied by the fluctuations in symptoms and dyskinesia, and these complications are an extremely important factor that adversely affects the quality of life. The hyperactivity of glutamate NMDA receptors of th...
Main Authors: | V. V. Poleshchuk, S. N. Illarioshkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-05-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2473 |
Similar Items
-
AMANTADINES: EXPERIENCE OF APPLICATION FOR PARKINSON DISEASE
by: A. A. PILIPOVICH, et al.
Published: (2016-12-01) -
Early stages of Parkinson’s disease: aspects of the diagnosis and therapy
by: A. A. Pilipovich
Published: (2019-12-01) -
Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
by: Aryun Kim, et al.
Published: (2018-05-01) -
Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018-04-01) -
Practical aspects of prescribing antiparkinsonian drugs. The place of amantadines in the management of Parkinson’s disease
by: N. V. Titova, et al.
Published: (2021-03-01)